← Back to Search

Monoclonal Antibodies

LY4100511 Dose 3 for Plaque Psoriasis

Phase 2
Waitlist Available
Research Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization
* Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12
Awards & highlights

Summary

The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.

Who is the study for?
This trial is for adults with moderate-to-severe plaque psoriasis. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be excluded based on other medical conditions or treatments.
What is being tested?
The study is testing the safety and effectiveness of a new medication called LY4100511 compared to a placebo in treating plaque psoriasis. This phase 2 trial will help determine the appropriate dose range for future studies.
What are the potential side effects?
While specific side effects of LY4100511 are not listed, common side effects for psoriasis medications can include skin irritation, headaches, fatigue, nausea, and potential impacts on liver function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the by the investigator to be related to study drug administration

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY4100511 Dose 3Experimental Treatment1 Intervention
Participants will receive LY4100511 orally.
Group II: LY4100511 Dose 2Experimental Treatment1 Intervention
Participants will receive LY4100511 orally.
Group III: LY4100511 Dose 1Experimental Treatment1 Intervention
Participants will receive LY4100511 orally.
Group IV: PlaceboPlacebo Group1 Intervention
Placebo administered orally.

Find a Location

Who is running the clinical trial?

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyLead Sponsor
7 Previous Clinical Trials
457 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,360 Previous Clinical Trials
418,440 Total Patients Enrolled
~147 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top